Atossa Therapeutics Inc
Company Overview
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing innovative medicines in areas of significant unmet medical need in oncology and infectious diseases. The company's lead product candidate is Endoxifen, which is in development for the treatment and prevention of breast cancer. Additionally, they are developing AT-301, a nasal spray being developed as a potential treatment for COVID-19.
The company is currently in the research and development phase and does not generate revenue from product sales. Their business model is focused on developing therapeutic candidates through clinical trials with the goal of eventual FDA approval and commercialization.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Atossa Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.